Results 51 to 60 of about 31,381 (233)

A Chemical Framework for Engineering Extracellular Vesicles’ Biointerface to Advance Precision Therapeutics

open access: yesAdvanced Materials, EarlyView.
Extracellular vesicles (EVs) are cell‐derived nanoparticles that mediate intercellular communication through their dynamic biointerfaces. Owing to their intrinsic biological functions, EVs have emerged as promising platforms for biomedical applications.
Leila Pourtalebi Jahromi   +3 more
wiley   +1 more source

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

open access: yesAdvanced Science
The ubiquitin‐editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20‐mediated IKK ...
Fan Luo   +12 more
doaj   +1 more source

LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer

open access: yesMolecular Therapy: Nucleic Acids, 2020
Oxaliplatin resistance is a major challenge in the clinical treatment for advanced colorectal cancer (CRC). Long non-coding RNAs (lncRNAs) are involved in tumorigenesis and progression as critical regulators, while their potential roles in ...
Xiangfeng Meng   +8 more
doaj   +1 more source

TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.

open access: yesPLoS ONE, 2023
Acquired resistance to oxaliplatin is considered as the primary reason for failure in colorectal cancer (CRC) therapy. Identifying the underlying resistance mechanisms may improve CRC treatment.
Tayebeh Cheraghi-Shavi   +2 more
doaj   +1 more source

Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion

open access: yesAdvanced Materials, EarlyView.
An engineered Trojan Mycobacterium, developed via a “peeling‐off and masking‐up” strategy, functions as a powerful splenic myelopoiesis converter. This spleen‐targeted nanomedicine induces trained immunity to reprogram immunosuppressive myeloid reservoirs into antitumoral effectors.
Jin‐Ho Choi   +5 more
wiley   +1 more source

MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells

open access: yesArtificial Cells, Nanomedicine, and Biotechnology, 2019
Oxaliplatin resistance limits the efficiency of treatment for colorectal cancer (CRC). Studies have shown that abnormal expression of microRNAs (miRNAs) were associated with tumorigenesis, cancer development and chemoresistance. The purpose of this study
Hui Liang   +8 more
doaj   +1 more source

Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer

open access: yesAdvanced Science, 2023
Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer (CRC); however, frequent drug resistance limits its therapeutic efficacy in patients.
Kaixuan Zeng   +7 more
doaj   +1 more source

Mitochondria and Neuromast Tagging With Fluorescent Gallium‐Triapine Analogues: In Cellulo MP FLIM and Zebrafish Live Imaging

open access: yesAdvanced Science, EarlyView.
Fluorescent BODIPY‐conjugated thiosemicarbazone ligands and their Ga(III), In(III), and Fe(III) complexes, inspired by Triapine, are developed as theranostic agents. Multiphoton FLIM and confocal microscopy in cancer cells and zebrafish reveal real‐time uptake, mitochondrial localisation, and whilst spectroscopic assays indicated preserved complex ...
Megan J. Green   +15 more
wiley   +1 more source

NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines

open access: yesMolecular Cancer, 2011
Background YB-1 is a multifunctional protein that affects transcription, splicing, and translation. Overexpression of YB-1 in breast cancers causes cisplatin resistance. Recent data have shown that YB-1 is also overexpress in colorectal cancer.
Tsofack Serges P   +7 more
doaj   +1 more source

ANXA2+ Small Extracellular Vesicles Drive Chemoresistance in Anaplastic Thyroid Cancer by Promoting XRCC5 Lactylation and Enhancing Non‐Homologous End‐Joining Repair

open access: yesAdvanced Science, EarlyView.
ANXA2+ sEVs promote cisplatin resistance in ATC by stabilizing the SRC/LDHA interaction, increasing LDHA phosphorylation and activity, and lactate production. Elevated lactate levels promote KAT5‐mediated lactylation of XRCC5 at lysine 265, enhancing its binding to XRCC6.
Shanshan Su   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy